Journal of clinical gastroenterology最新文献

{"title":"The Association of Free Testosterone Levels With Frailty Metrics in Advanced Chronic Liver Disease.","authors":"Miguel Sogbe, Brittany Bromfield, Roberto Tellez, Pamela M Bloomer, Jaime Herrera-Caceres, Christopher B Hughes, Michael A Dunn, Andres Duarte-Rojo","doi":"10.1097/MCG.0000000000002192","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002192","url":null,"abstract":"<p><strong>Background: </strong>Frailty is common in advanced chronic liver disease (AdvCLD). Key assessment tools for frailty in this population include the liver frailty index (LFI), the 6-minute walk test (6MWT), and the gait speed test (GST). This study investigates the relationship between free testosterone (FT) levels and these frailty measures in men with AdvCLD.</p><p><strong>Methods: </strong>In this prospective cohort study of 197 male AdvCLD patients awaiting liver transplantation, frailty was assessed using the LFI, 6MWT, and GST. Participants were classified as having low or normal FT levels, and associations with frailty measures were analyzed using multivariable linear and logistic regression models.</p><p><strong>Results: </strong>Of the 197 patients, 41 (20.8%) had low FT levels. This group was more likely to have a higher Child-Turcotte-Pugh class, higher MELD-Na scores, and a history of hepatic encephalopathy compared with patients with normal FT levels (P<0.05). Those with low FT also demonstrated greater frailty, with significantly poorer performance on the LFI and shorter distances on the 6MWT (P<0.05); the GST difference did not reach statistical significance (P=0.106). In multivariable regression analysis, including age, MELD-Na score, and Child-Turcotte-Pugh score, only low FT levels (OR: 2.4, P=0.043) were independently associated with frailty. Similarly, in multivariable linear regression, FT levels were independently associated with LFI scores and 6MWT (P<0.05).</p><p><strong>Conclusion: </strong>Low FT is associated with increased frailty in male patients with AdvCLD. Additional research may help identify therapeutic approaches to improve frailty in this patient group.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Lactulose Breath Test can Predict Refractory Gastroesophageal Reflux Disease by Measuring Bacterial Overgrowth in the Small Intestine.","authors":"Pelin Telli, Aynura Rustamzada, Bilger Çavuş","doi":"10.1097/MCG.0000000000002226","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002226","url":null,"abstract":"","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting Diagnostic Yield of Video Capsule Endoscopy in Celiac Disease: A Methodological Perspective.","authors":"Javier Arredondo Montero","doi":"10.1097/MCG.0000000000002225","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002225","url":null,"abstract":"","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive Incremental Pregabalin Therapy Leads to Better Pain Relief in Patients With Chronic Pancreatitis: A Double-blind Randomized Controlled Trial.","authors":"Randeep Rana, Samagra Agarwal, Sumaira Qamar, Srikanth Gopi, Renu Bhatia, Kumble Seetharama Madhusudhan, Deepak Gunjan, Anoop Saraya","doi":"10.1097/MCG.0000000000002173","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002173","url":null,"abstract":"<p><strong>Objectives: </strong>Gabapentinoids like pregabalin have been inadequately explored in patients with painful chronic pancreatitis (CP) on a long-term basis. The objective was to study the pain relief on pregabalin as an adjunct therapy for 12 weeks in painful CP.</p><p><strong>Materials and methods: </strong>In this double blind, randomized placebo-controlled trial, patients with painful CP with no ongoing inflammation(no pseudocyst/inflammatory head mass) or significant obstruction were randomized to receive either incremental doses of pregabalin or placebo for 12 weeks. The primary outcome was change in Izbicki pain score. Change in the quality of life (QoL) (SF-36 questionnaire), interference of pain with daily life [modified brief pain inventory- short form (mBPI-SF)] and patients' global impression of change (PGIC) were assessed as secondary outcomes. Tolerability and adverse effects were noted as safety outcomes. As an exploratory outcome, the role of quantitative sensory testing (QST) to predict patients' response to pregabalin was assessed.</p><p><strong>Results: </strong>Fifty-five patients with painful CP (age 29.9±10.6 y; 79% males; median illness duration 36 mo) were randomized to receive pregabalin (n=30) or placebo (n=25). Change in Izbicki pain score was significantly better in pregabalin group [pregabalin: -23.75 (IQR: -9.69 to -43.75) versus placebo: -8.75 (3.44 to -17.50); P=0.005]. Overall QoL and PGIC were also better and interference of pain with daily activities reduced in the pregabalin group [median change BPI severity pregabalin: -1.83 (-0.83 to -3.75) versus placebo: -0.67 (0.33 to -1.42); P=0.008; BPI interference pregabalin: -2.64 (-0.33 to -5.21) versus placebo: -0.43 (1.18 to -2.29); P=0.009]. Frequent adverse events included sleepiness (51.7%) and giddiness (58%) but drug discontinuation occurred in only 10.4% of patients. No QST parameters could predict pain response to pregabalin.</p><p><strong>Conclusions: </strong>Pregabalin is a useful adjunct to pain management in patients with CP.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastro-Entero-Colic Fistula After Successful EUS Guided Gastroenterostomy: Initial Lessons Learned From an International Cohort.","authors":"Antonio Mendoza Ladd, Michel Ladna, Luke Pecha, Enrique Perez Cuadrado, Kaveh Sharzehi, Meera Bhardwaj, Samuel Han, Jorge Vargas, Sumant Inamdar, Khanh Do-Cong Pham, Olaya Brewer, Christoph Schlag, Pieter Hindryckx, Tomas Hucl, Amrita Sethi, Viliam Masaryk, Harshit Khara","doi":"10.1097/MCG.0000000000002178","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002178","url":null,"abstract":"<p><strong>Background: </strong>EUS-guided gastroenterostomy (EUS-GE) is an effective option for the management of gastric outlet obstruction (GOO). Due to the poor prognosis of patients undergoing it, data on its long-term adverse events (AE) is scarce. Herein, we describe a cohort of patients with gastro-entero-colic fistula (GECF) as a late AE of previously successful EUS-GE.</p><p><strong>Methods: </strong>Patients who developed a GECF after EUS-GE from 10 high-volume centers were analyzed. Information collected included demographic characteristics, indications, clinical and technical success rates, stent type and size, fistula characteristics, management, and outcomes.</p><p><strong>Results: </strong>Sixteen cases were identified. The mean interval from index EUS-GE to the diagnosis of GECF was 4 to 8 weeks. The most common cause of GOO was pancreatic adenocarcinoma (PDAC). The transverse colon was the most common site for the GECF (14 patients). A 20×10 mm lumen apposing metal stent (LAMS) was utilized in 10 patients. Endoscopic management with a variety of modalities was successful in 13 cases. Follow-up interval after endoscopic management of the fistula averaged 2 to 4 weeks. At the time of the manuscript elaboration, 10 patients had died, 5 were alive, and 1 was lost to follow-up.</p><p><strong>Conclusions: </strong>This is the first description of a cohort of patients with GECF after EUS-GE. The exact mechanisms leading to GECF in these cases are unknown. Possible explanations include inadvertent colon puncture during the index procedure and/or entrapment of mesocolon. More data is needed to further characterize this AE.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Helicobacter pylori Infection Status and Clarithromycin-resistant Strains in Patients With Gastric Mucosa-associated Lymphoid Tissue Lymphoma Using Real-time Polymerase Chain Reaction: A Single-center Korean Study.","authors":"Joo Yeon Koo, Nah Ihm Kim, Sung Sun Kim, Ji Young Lee, Jae-Hyuk Lee, Sook In Jung, Tae Mi Yoon, Jong-Hwan Park, Wan-Sik Lee, Sung-Bum Cho, Kyung-Hwa Lee","doi":"10.1097/MCG.0000000000002182","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002182","url":null,"abstract":"<p><strong>Background: </strong>Helicobacter pylori (HP) is a well-known risk factor for gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, the prevalence of clarithromycin-resistant (CLR) HP strains in patients with gastric MALT lymphoma compared with the general population is largely unknown.</p><p><strong>Materials and methods: </strong>HP test was performed on samples from 4686 patients who underwent gastric biopsy, including 89 patients who were diagnosed with gastric MALT lymphoma. HP infection and resistant strains (A2142G and A2143G) were investigated using real-time polymerase chain reaction.</p><p><strong>Results: </strong>HP was detected in 1964 out of 4597 cases in the non-MALT control group (42.7%), while HP infection was present in 51 out of 89 cases (57.3%) in the gastric MALT lymphoma group (P=0.006). The frequency of CLR strains was 39.2% (20 out of 51 cases) in the gastric MALT lymphoma group, which was significantly higher than the rate of 26.8% (527 out of 1964 cases) in the non-MALT control patient group (P=0.049). The proportion of the resistant strain A2142G was higher in the gastric MALT lymphoma group (20.0%, 4/20) than in the non-MALT control patient group (11.0%, 58/527), with marginal statistical significance (P=0.093).</p><p><strong>Conclusions: </strong>The significantly higher infection rate of CLR HP in patients with gastric MALT lymphoma suggests a reduced likelihood of successful tumor regression using clarithromycin-based first-line eradication therapy.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malnutrition and Opioid Use Disorder Are Associated With Higher 30-day Readmission Rates in Patients Admitted for Ulcerative Colitis.","authors":"Tarek Odah, Pedro Palacios, Marianny Sulbaran, Daniela Fluxa, Jami Kinnucan, Michael F Picco, Jana G Hashash, Francis A Farraye","doi":"10.1097/MCG.0000000000002189","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002189","url":null,"abstract":"<p><strong>Background and goals: </strong>Ulcerative colitis (UC) readmissions to the hospital pose a burden to patients and health care systems. Preventing readmissions is important for the quality of care and quality of life of patients with UC. We aimed to identify the incidence of 30 and 90-day readmissions and its predictors in patients with UC.</p><p><strong>Study: </strong>Retrospective review of the 2018 National Readmission Database (NRD) of adult patients readmitted after an index admission (IA) of UC. ICD-10CM/PCS codes were used to identify patients with UC, other comorbidities, and procedures. We identified the most common causes for readmission and independent risk factors for readmission were identified using Cox regression analysis.</p><p><strong>Results: </strong>The 30 and 90-day readmission rates for UC in 2018 were 16.6% and 28.3%. In-hospital mortality and mean length of stay were higher in patients readmitted within both 30 and 90 days. Independent predictors of 30-day readmission were higher Charlson Comorbidity Index (CCI), undergoing ileostomy, increasing length of stay, malnutrition and opioid use disorder at IA. In the 90-day readmission cohort, independent predictors were CCI score of 2 or ≥3, developing shock, admission to large bed size hospitals, undergoing colectomy, increasing length of stay and opioid use disorder at IA. The number one readmission cause at 30 and 90 days was sepsis of unspecified organism.</p><p><strong>Conclusion: </strong>Readmission is associated with higher mortality and is associated with risk factors such as malnutrition, undergoing ileostomy during IA and opioid use disorder. Readmissions in UC continue to pose a high burden to patients and our health care system.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Immunochemical Tests for Colorectal Cancer Screening: Mailed Outreach Outperforms In-Clinic Outreach With Phone Calls Being the Most Effective Reminder Strategy.","authors":"Kanika Malani, Gabriel Dayanim, Jennifer Ouellette, Yetunde Shittu, Theresetta Myers, Yousef Elfanagely, Kirsten Loscalzo, Kittichai Promrat","doi":"10.1097/MCG.0000000000002183","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002183","url":null,"abstract":"<p><strong>Goals: </strong>This study aimed to (1) compare colorectal cancer (CRC) screening rates among patients receiving mailed fecal immunochemical testing (FIT) versus in-clinic FIT and (2) assess the impact of various reminder interventions versus no extra reminder on mailed FIT completion.</p><p><strong>Background: </strong>FIT is a first-line method for CRC screening. However, no research has compared screening completion in patients receiving FIT through mail (mailed FIT) versus patients receiving FIT from a provider in a clinic setting (in-clinic FIT), both of which have significantly different workflows. Furthermore, limited research has compared whether varying reminder strategies improve mailed FIT completion.</p><p><strong>Study: </strong>This quality improvement prospective cohort study conducted at the Providence Veterans Affairs Medical Center included patients due for average-risk CRC screening. Sixteen hundred patients were mailed FIT, and if FIT was not returned within 1 month they were randomized to the following reminders: no extra reminder, personal phone call, personal voicemail, mailed postcard. Simultaneously, 1769 patients received in-clinic FIT. Three-month return and result rates were compared between mailed versus in-clinic FIT, as well as across the different mailed FIT reminder interventions.</p><p><strong>Results: </strong>Mailed FIT return (36%) and result (34%) rates were significantly higher than in-clinic FIT return (28%) and result (24%) rates (both P<0.0001). Phone calls were the most effective mailed FIT reminder (29% return rate), significantly outperforming the no extra reminder group (21% return rate, P=0.02).</p><p><strong>Conclusions: </strong>Mailed FIT demonstrated higher efficacy and should be implemented in conjunction with in-clinic FIT. Phone call reminders should be incorporated into the mailed FIT workflow.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of MRI Functional Liver Imaging Score and Spontaneous Portal Shunt for First Decompensation in Patients With Chronic Hepatitis B.","authors":"Jie Zou, Fei Jia, Yanli Jiang, Pin Yang, Fengxian Fan, Pengfei Wang, Haoyuan Li, Yuan Ding, Kai Ai, Jing Zhang","doi":"10.1097/MCG.0000000000002221","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002221","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the predictive value of Gd-EOB-DTPA enhanced MRI functional liver imaging score and spontaneous portal shunt on the occurrence of first hepatitis decompensation in patients with chronic hepatitis B (CHB).</p><p><strong>Methods: </strong>Clinical and MRI data of 443 patients with CHB who received Gd-EOB-DTPA enhanced MRI scanning from October 2019 to October 2022 were retrospectively collected. All patients had a complete clinical laboratory examination 1 week before and after MR examination. According to the FIB-4 score and Child-Pugh(CP) grading criteria, the patients were divided into 4 groups: CLD group, CPA group, CPB group, and CPC group. The correlation between clinical laboratory indicators such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), and imaging parameters such as functional liver imaging score (FLIS), spontaneous portosystemic shunt (SPSS), splenic craniocaudal diameter (SCCD), portal vein width and splenic vein width of patients in different groups was compared. Intragroup correlation coefficient (ICC) was used to evaluate the consistency of FLIS, SPSS and SCCD results among different observers. The ROC curve was used to compare the diagnostic efficiency of each imaging parameter for different groups of patients. The laboratory and imaging parameters that differed across groups were analyzed using Cox regression to evaluate the predictive efficacy of each parameter for the occurrence of first liver decompensation in patients with high-risk CHB in the CLD group and the CPA and CPB groups.</p><p><strong>Results: </strong>FLIS and its 3 parameters (EnQS, ExQS, and PVQS) were moderately strongly correlated with clinical groups (r=-0.370 to -0.543, P<0.001). The consistency of FLIS and its 3 quantitative parameters among different observers was high (r=0.965, P<0.001). SCCD and AUC of 0.844 (95% CI: 0.792-0.896) were the optimal parameters for distinguishing LC between the CLD group and the CPA group. The best FLIS criteria for predicting LC in CLD/CPA groups and for predicting LC in CPA/B groups were ≥4. The AUC for the differentiation of LC from CPB/C in the CLD/CPA groups was 0.801 (95% CI: 0.759-0.843), while the AUC for CPB and CPC was 0.858 (95% CI: 0.813-0.903). FLIS is not an independent predictor of first hepatitis decompensation in patients with CHB. Univariate analysis showed that SPSS, SCCD≥14.36 cm, age, and AST were independent risk factors for first hepatitis decompensation. The dichotomy of SPSS combined with SCCD can provide a better predictor of the first hepatitis decompensation event.</p><p><strong>Conclusion: </strong>FLIS has the best diagnostic efficacy in classifying liver function in patients with CHB. SPSS and SCCD have high predictive value in predicting the first hepatitis decompensation event in the CLD group and the CPA and CPB groups.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144674919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Population-Based Assessment of Physical Activity and Exercise in Persons With IBD.","authors":"Sydney Chochinov, Casandra Dolovich, Gia Ly, Adebanke Oketola, Samuel Narvey, Maitreyi Raman, Sandra Webber, Charles N Bernstein","doi":"10.1097/MCG.0000000000002220","DOIUrl":"https://doi.org/10.1097/MCG.0000000000002220","url":null,"abstract":"<p><strong>Goals/background: </strong>We aimed to assess the physical activity (PA) and exercise profiles of persons with IBD, their limitations in undertaking PA/exercise, and how PA correlates with active disease and fatigue in a Canadian population-based sample.</p><p><strong>Study: </strong>A cross-sectional survey study was undertaken by participants in the University of Manitoba IBD Research Registry. The survey included sociodemographic factors, PA/exercise, the International Physical Activity Questionnaire (IPAQ), Inflammatory Bowel Disease Symptom Inventory (IBDSI), and Modified Fatigue Impact Scale (MFIS). Bivariate and logistic regression analyses assessed the association between PA and disease activity and fatigue.</p><p><strong>Results: </strong>The survey was completed by 1257 of 2740 invitees (45.8%). Because of 163 missing age or PA responses, 1094 were included in the data analysis. The mean age of participants was 60.8+/-13.0 years. Activity status was inactive in 42.5%, moderately active in 32.0%, and highly active in 25.5%. Activity levels were similar for those >55 versus those <55 years. Thirty-eight percent reported that IBD never impacted their PA/exercise. Persons with Crohn's disease were more likely to be inactive than persons with ulcerative colitis. Logistic regression analysis showed that the odds of engaging in lower levels of PA were greater for persons with active IBDSI versus persons with non-active IBDSI (aOR: 1.51, 95% CI: 1.11-2.04), with an increase in MFIS score (aOR: 1.02, 95% CI: 1.01-1.03), in females with ulcerative colitis, and in those who smoke.</p><p><strong>Conclusion: </strong>These findings underscore the need for tailored PA/exercise guidelines for individuals with IBD. Future research should explore objective measures of PA to better understand PA/exercise in both younger and older adult populations.</p>","PeriodicalId":15457,"journal":{"name":"Journal of clinical gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}